Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA has approved Bixlenvo, a once-daily single-tablet HIV regimen combining bictegravir and lenacapavir — making it the smallest pill of its kind. Developed by Gilead Sciences, it's designed for virologically suppressed adults who can't tolerate other single-tablet options due to resistance or side effects. The approval is backed by data from the ARTISTRY-1 and ARTISTRY-2 trials.
The FDA has given the green light to Bixlenvo, a once-daily single-tablet HIV regimen developed by Gilead Sciences — and it's being called the smallest pill of its kind. The new combo brings together two of Gilead's existing drugs: bictegravir, a guideline-recommended integrase strand transfer inhibitor, and lenacapavir, a first-in-class capsid inhibitor. It's specifically designed for virologically suppressed adults who are currently on complex, multi-pill regimens but can't switch to other available single-tablet options due to pre-existing resistance or tolerability issues.
The accelerated approval was supported by results from the ARTISTRY-1 and ARTISTRY-2 trials — presented at the Conference on Retroviruses and Opportunistic Infections earlier this year, with ARTISTRY-1 also published in The Lancet. Both trials confirmed that patients who switched to Bixlenvo maintained viral suppression. The regimen requires a 2-day lenacapavir initiation dose before transitioning to the daily pill.
Key Takeaways:
Why it matters: For people aging with HIV on complicated regimens, Bixlenvo offers a meaningful simplification — without sacrificing efficacy. It fills a real gap for patients whose needs weren't met by existing single-tablet therapies.
